Biohaven Pharmaceutical shares are declining today after a partial FDA clinical hold on its lead epilepsy candidate and a subsequent analyst downgrade. The market reaction indicates investor focus on the company's clinical development timeline and current valuation.

Pharmaceutical company Pfizer Inc. (Pfizer), on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), has agreed to pay $59,746,277 to resolve allegations that...

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V....

Biohaven has ​entered into ‌a licensing agreement ​with ​South Korean drug ⁠maker ​SK Biopharmaceuticals ​for Biohaven's epilepsy drug ​platform, ​including Opakalim, for ‌up ⁠to $795 million, the companies ​said ​in ⁠a statement ​on ​Wednesday.

The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.

Yale University and Biohaven Therapeutics Ltd. won a combined $4 million in a trade-secrets and breach-of-contract trial in Delaware related to drug-development technology.

Browse our gallery of floating island photos showcasing BioHaven® technology in action. See how our solutions enhance water quality and ecosystems through vivid imagery.

Biohaven said on Wednesday its experimental depression drug did not meet the main goal of a mid-stage trial, adding to a string of trial and regulatory setbacks for the drugmaker this year.

Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of ​its experimental epilepsy drug after rodent findings, sending its ‌shares down more than 13% in premarket trading.

Clinical Research Center of UConn School of Medicine teaming with Connecticut’s Biohaven Pharmaceuticals, Inc. for innovative clinical trial targeting the r ...

RISE: A Clinical Trial For Epilepsy I recently had the opportunity to speak with Anne Neumann, RN, BSN, Rare Disease Marketing, Patient Advocacy and Engagement Lead at Biohaven, about her role and about RISE: A Clinical Trial For Epilepsy. Background on Ms. Neumann Anne brings over 25 years’ experience in healthcare, from nonprofit to clinical practice to various roles with the pharmaceutical industry.

BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat the neuroinflammation and immune dysregul...

Biohaven announces exciting new clinical findings for Opakalim, a promising epilepsy treatment, showcasing enhanced seizure control and tolerability.

Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.

Pharmaceutical company Pfizer Inc. (Pfizer), on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), has agreed to pay $59,746,277 to resolve allegations that...

In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function...

RBC's $22 price target implies an upside of 74% for shares of Biohaven.

This one hurts. 😬 FDA slapping Biohaven with a CRL for its SCA drug--after collaborating on trial design and endpoint = OUCH!!! - Second rejection this week (see uniQure). - FDA now questioning ...